1. Home
  2. NVNI vs ICCC Comparison

NVNI vs ICCC Comparison

Compare NVNI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

N/A

Current Price

$1.31

Market Cap

12.9M

Sector

N/A

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$6.65

Market Cap

55.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
ICCC
Founded
2019
1982
Country
Brazil
United States
Employees
618
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
55.5M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
NVNI
ICCC
Price
$1.31
$6.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
83.8K
11.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.33
EPS
N/A
0.20
Revenue
N/A
$26,493,169.00
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
$32.70
Revenue Growth
N/A
51.64
52 Week Low
$0.14
$4.32
52 Week High
$4.94
$7.60

Technical Indicators

Market Signals
Indicator
NVNI
ICCC
Relative Strength Index (RSI) 37.97 56.18
Support Level $1.10 $5.72
Resistance Level $1.64 $6.87
Average True Range (ATR) 0.14 0.23
MACD 0.04 0.01
Stochastic Oscillator 40.00 87.62

Price Performance

Historical Comparison
NVNI
ICCC

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: